The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be worthwhile targets for new MASH therapies. The scientists published their work ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

U ntil recently, no treatments were available to help slow the progression of metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. But in March 2024 ...